In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates

Autor: Mahdi Abastabar, Arezoo Zaedi, Shafigheh Shabanzadeh, Mohsen Nosratabadi, Maryam Moazeni, Seyed Reza Aghili, Iman Haghani, Shaghayegh Khojasteh, Javad Javidnia, Sanaz Nargesi, Tahereh Shokohi, Mohammad Taghi Hedayati, Jacques F. Meis, Hamid Badali
Rok vydání: 2022
Předmět:
Zdroj: Mycoses. 65:981-988
ISSN: 1439-0507
0933-7407
DOI: 10.1111/myc.13481
Popis: The treatment of invasive aspergillosis caused by cryptic species remains a challenge due to the lack of randomised clinical trials and investigation of the efficacy and safety of different therapeutic strategies. We aimed to evaluate the in vitro activity of 23 conventional and new antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates by using the Clinical and Laboratory Standards Institute (CLSI) standard M38-A3. The lowest geometric mean MIC values were found for luliconazole and lanoconazole (0.001 μg/ml), followed by anidulafungin (0.104 μg/ml), posaconazole (0.15 μg/ml), itraconazole (0.37 μg/ml), efinaconazole (0.5 μg/ml), voriconazole (0.51 μg/ml), tavaborole (0.72 μg/ml), and amphotericin B (0.79 μg/ml). In contrast, ketoconazole, terbinafine, econazole, tioconazole, ravuconazole, miconazole, nystatin, clotrimazole, griseofulvin, sertaconazole, natamycin, tolnaftate, and fluconazole had no or low activity. Further studies are required to determine how well this in vitro activity translates into in vivo efficacy.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje